Naloxone (Narcan) Dosing and Administration for Opioid Overdose
For suspected opioid overdose in adults and children, administer one 4 mg intranasal spray (or 0.4-2 mg IV/IM) as the initial dose, repeating every 2-3 minutes with alternating nostrils if no response, while prioritizing airway support and immediate activation of emergency services. 1, 2
Initial Dose and Route Selection
Intranasal Administration (Preferred for Lay Responders)
- Initial dose: One 4 mg spray in one nostril for both adults and children 2
- No priming or testing required; each device contains a single dose 2
- Bioavailability approximately 50% compared to intramuscular route, with median time to peak concentration of 15-30 minutes 3
- Position patient supine, tilt head back, insert nozzle fully into nostril, and press plunger firmly 2
Parenteral Administration (Healthcare Settings)
- IV/IM/IO: 0.4-2 mg initial dose for adults 1, 2
- Pediatric dosing: 0.1 mg/kg IV/IM/IO (maximum 2 mg for children ≥5 years or ≥20 kg) 1
- IV route facilitates dose titration and has fastest onset (within 2 minutes) 2, 4
- IM route has slower onset but avoids needle exposure concerns in field settings 4
Repeat Dosing Protocol
Timing and Frequency
- Repeat every 2-3 minutes if patient does not respond or relapses into respiratory depression 1, 2
- Alternate nostrils with each intranasal dose 2
- Duration of action is 1-2 hours for IV route, potentially longer for IM/intranasal 3, 5
- Most opioids have longer duration than naloxone, necessitating repeated doses and prolonged observation 1, 2
Response Assessment
- Goal is restoration of adequate spontaneous breathing, NOT full consciousness 1, 5
- If no response after 2-3 minutes, administer additional dose using new device 2
- Continue dosing every 2-3 minutes until emergency medical services arrive 2
- After response, observe continuously for recurrence of respiratory depression (minimum 2 hours for naloxone, 4-8 hours for longer-acting opioids) 1
Critical Management Priorities
Airway and Breathing First
- Standard BLS/ALS measures take absolute priority over naloxone administration 1
- For respiratory arrest with definite pulse: provide rescue breathing or bag-mask ventilation while administering naloxone 1
- For cardiac arrest: focus on high-quality CPR; naloxone administration should not delay compressions 1
- No studies demonstrate improved outcomes from naloxone during cardiac arrest 1
Emergency Activation
- Activate emergency medical services immediately after first dose; do not wait for patient response 1, 2
- Place patient in recovery position (on side) after administration 2
- Rescuers cannot reliably determine if respiratory depression is solely opioid-induced 1
Special Considerations
Synthetic Opioids (Fentanyl)
- May require higher or more frequent naloxone doses than heroin overdoses 3, 6
- Initial 2-4 mg intranasal dose is most commonly used in current practice 6
- Have multiple doses available, as single doses may be insufficient 3
Partial Agonists (Buprenorphine, Pentazocine)
- Reversal may be incomplete and require higher naloxone doses or repeated administration 2
- Standard dosing protocol applies, but anticipate need for additional doses 2
Opioid-Dependent Patients
- Risk of precipitated withdrawal with higher doses 1, 5
- In healthcare settings with opioid-tolerant patients, consider lower initial doses (0.04-0.05 mg IV) titrated to respiratory effect 7, 5
- For suspected overdose in community settings, standard dosing takes precedence over withdrawal concerns 1, 2
- Do not administer to neonates of mothers with long-term opioid use due to seizure risk 1
Common Pitfalls to Avoid
- Never delay CPR or rescue breathing to administer naloxone 1
- Never assume single dose will be sufficient—have multiple doses immediately available 2, 3
- Never discharge patients after brief observation—respiratory depression can recur as naloxone wears off 1
- Never test or prime intranasal devices—this wastes the single dose 2
- Never reuse naloxone nasal spray devices—each contains only one dose 2